Characterization of residual microRNAs in AAV vector batches produced in HEK293 mammalian cells and Sf9 insect cells.
AAV vectors
HEK293 mammalian cells
Sf9 insect cells
bioproduction
gene therapy
microRNA
quality control
residual nucleic acids
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
27
02
2024
accepted:
23
07
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
epublish
Résumé
With more than 130 clinical trials and 8 approved gene therapy products, adeno-associated virus (AAV) stands as one of the most popular vehicles to deliver therapeutic DNA
Identifiants
pubmed: 39220637
doi: 10.1016/j.omtm.2024.101305
pii: S2329-0501(24)00121-9
pmc: PMC11365364
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101305Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
M.P.-B. and E.A. are inventors of patents related to AAV gene therapy licensed to biopharma companies.